Download MendeleyDiscovery of TP0628103: A Highly Potent and Selective MMP-7 Inhibitor with Reduced OATP-Mediated Clearance Designed by Shifting Isoelectric Points.
Oka, Y., Abe-Sato, K., Tabuse, H., Yasukawa, Y., Yahara, T., Nishimoto, T., Kamitani, M., Fukunaga, T., Ochiai, N., Kumasaka-Abe, T., Hitaka, K., Gunji, E., Ohara, H., Takeda, T., Kojima, N., Asami, T.(2024) J Med Chem 67: 1406-1420
- PubMed: 38214909 Search on PubMed
- DOI: https://doi.org/10.1021/acs.jmedchem.3c01967
- Primary Citation Related Structures:
8K4Z - PubMed Abstract:
Matrix metalloproteinase-7 (MMP-7) has been shown to play an important role in pathophysiological processes such as cancer and fibrosis. We previously discovered selective MMP-7 inhibitors by molecular hybridization and structure-based drug design. However, the systemic clearance (CL tot ) of the biologically active lead compound was very high. Because our studies revealed that hepatic uptake by organic anion transporting polypeptide (OATP) was responsible for the high CL tot , we found a novel approach to reducing their uptake based on isoelectric point (IP) values as an indicator for substrate recognition by OATP1B1/1B3. Our "IP shift strategy" to adjust the IP values culminated in the discovery of TP0628103 ( 18 ), which is characterized by reduced in vitro OATP-mediated hepatic uptake and in vivo CL tot . Our in vitro - in vivo extrapolation of OATP-mediated clearance and the "IP shift strategy" provide crucial insights for a new medicinal chemistry approach to reducing the systemic clearance of OATP1B1/1B3 substrates.
- Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan.
Organizational Affiliation:
